You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
國藥集團中國生物研發新冠滅活疫苗即將開始國際臨床三期研究
阿思達克 06-24 07:36
國藥集團中國生物宣布,其研發的新冠滅活疫苗即將在阿聯酋開始國際臨床三期研究,標誌著全球首個新冠滅活疫苗國際臨床試驗正式啟動。

國家科技部、國家衛健委早前通報,內地科研攻關團隊按照滅活疫苗、基因工程重組亞單位疫苗、腺病毒載體疫苗、減毒流感病毒載體疫苗和核酸疫苗等5條技術路線,共布局12項疫苗研發任務。

目前,已對1個腺病毒載體疫苗、1個重組亞單位新冠疫苗、4個滅活疫苗開展臨床試驗,約佔全世界開展臨床試驗疫苗總數的四成。

除國藥集團外,康希諾與陳薇院士團隊研發的新冠病毒疫苗已經在加拿大衛生部獲批開展臨床試驗;北京科興也與巴西生物研究機構宣布合作開展臨床三期試驗。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account